-
Advances in Experimental Medicine and... 2019The goal of treatment for depressive disorders is complete remission of depressive symptoms with full recovery of social function and prevention of recurrence. However,... (Review)
Review
The goal of treatment for depressive disorders is complete remission of depressive symptoms with full recovery of social function and prevention of recurrence. However, a large proportion of patients do not experience symptomatic remission after the initial treatment, with even lower rates of remission in the longer treatment term. The main objective of individualized treatment applied in psychiatry is to improve precision in disease diagnosis, prognosis, treatment choices, and treatment response. Diverse approaches and techniques, such as genomics, epigenomics, other omics, neural circuit, and artificial intelligence are related to precision psychiatry. Using biology and computational psychiatry tools to find potential biomarkers, and based on precision psychiatry, patients considered to belong to the same endophenotype will be possible to receive biomarkers-based treatment and better prognosis. Especially in the choice of intervention, individualized treatment should be considered. In this review, we present the development of precise treatment in depressive disorders and introduce advances in several domains toward precision medicine and individualized treatment. We pay particular attention to biomarkers and the development of new technologies in depressive disorders, which will help disease complete remission and functional recovery, seek better lives for patients suffered with depressive disorders.
Topics: Biomarkers; Depressive Disorder; Epigenomics; Humans; Phenotype; Precision Medicine; Psychiatry
PubMed: 31784966
DOI: 10.1007/978-981-32-9271-0_12 -
Fortschritte Der Neurologie-Psychiatrie Apr 2022
Topics: Depression; Depressive Disorder; Humans; Parkinson Disease
PubMed: 35443281
DOI: 10.1055/a-1683-1840 -
Ugeskrift For Laeger Jan 2019
Topics: Alcoholism; Depressive Disorder; Humans; Suicide
PubMed: 30618368
DOI: No ID Found -
MMW Fortschritte Der Medizin Jun 2024
Topics: Humans; Depressive Disorder; Diabetes Mellitus, Type 2
PubMed: 38806899
DOI: 10.1007/s15006-024-4001-5 -
Praxis Jan 2018
Review
Topics: Aged; Antidepressive Agents; Cognitive Dysfunction; Combined Modality Therapy; Depressive Disorder; Diagnosis, Differential; Evidence-Based Medicine; Guideline Adherence; Humans; International Classification of Diseases; Psychotherapy; Risk Factors; Suicide; Suicide Prevention
PubMed: 29382263
DOI: 10.1024/1661-8157/a002883 -
Lakartidningen Jan 2019
Topics: Antidepressive Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder; Humans; Secondary Prevention
PubMed: 30644995
DOI: No ID Found -
The Psychiatric Clinics of North America Jun 2023Major depressive disorder is a substantial public health challenge impacting at least 3 million adolescents annually in the United States. Depressive symptoms do not... (Review)
Review
Major depressive disorder is a substantial public health challenge impacting at least 3 million adolescents annually in the United States. Depressive symptoms do not improve in approximately 30% of adolescents who receive evidence-based treatments. Treatment-resistant depression in adolescents is broadly defined as a depressive disorder that does not respond to a 2-month course of an antidepressant medication at a dose equivalent of 40 mg of fluoxetine daily or 8 to 16 sessions of a cognitive behavioral or interpersonal therapy. This article reviews historical work, recent literature on classification, current evidence-based approaches, and emerging interventional research.
Topics: Humans; Child; Adolescent; Depressive Disorder, Treatment-Resistant; Depressive Disorder, Major; Antidepressive Agents; Diagnosis, Differential; Treatment Outcome; Transcranial Magnetic Stimulation; Psychotherapy
PubMed: 37149350
DOI: 10.1016/j.psc.2023.02.007 -
Psychopathology 2020Since the introduction of DSM-III anhedonia has become a core depressive criterion and is defined as the loss of interest or pleasure. Although the origin of the word... (Review)
Review
Since the introduction of DSM-III anhedonia has become a core depressive criterion and is defined as the loss of interest or pleasure. Although the origin of the word goes back to the end of the 19th century and numerous anhedonic symptoms are described in classic texts on depression, this centrality in the diagnosis of depression is only recent. Anhedonia is best described as a symptom complex with unclear boundaries cutting across the tripartite model of the mind (affect, volition, and cognition). Popular concepts of anhedonia pertain to the pleasure cycle and positive affectivity. These concepts partially overlap and are often mixed up, but clearly stem from different theoretical backgrounds: the affective science of reward processing versus more general, dimensional modelling of affect. The former concept seems more suitable to understand anhedonic emotions, the latter more suitable to understand anhedonic mood or trait. This narrative review covers the history of "anhedonia," the different anhedonic phenomena, and psychopathological concepts. An attempt is made to go beyond a merely descriptive psychopathology. Neurobiological and psychological insights shed a light on how symptoms are made and interconnected; these insights possibly call for a new psychopathological language.
Topics: Adult; Anhedonia; Depressive Disorder; Female; Humans; Male
PubMed: 32668436
DOI: 10.1159/000508773 -
Psychodynamic Psychiatry 2019
Topics: Depressive Disorder; Humans; Psychotherapy, Psychodynamic
PubMed: 31107167
DOI: 10.1521/pdps.2019.47.2.127 -
Fortschritte Der Neurologie-Psychiatrie May 2018Depressive disorders are associated with various neurobiological alterations like hyperactivity of the hypothalamic-pituitary-adrenal axis, altered neuroplasticity and... (Review)
Review
Depressive disorders are associated with various neurobiological alterations like hyperactivity of the hypothalamic-pituitary-adrenal axis, altered neuroplasticity and altered circadian rhythms. Relating to the circadian symptoms, a process is adopted in which individual genetic factors together with social, psychological and physical stressors may lead to a decompensation of the circadian system. The causal connections between depressive disorders and disturbed circadian rhythms have not been completely clarified. Chronobiological therapy is based on these disturbed processes. For the treatment of the circadian symptoms, various scientifically tested chronotherapeutics are available with however different effectiveness and evidence like light therapy or sleep deprivation. The successful treatment of depression also frequently leads to a improvement in altered circadian rhythm.
Topics: Chronobiology Disorders; Circadian Rhythm; Depressive Disorder; Humans; Phototherapy
PubMed: 29843180
DOI: 10.1055/s-0043-123069